Analyst Rating Update for argenx SE ARGX
On June 24, 2026, Morgan Stanley analyst Matthew Harrison maintained his rating on argenx (ARGX) with an update in the price target. The new price target is set at $1180.00, reflecting a slight increase from the previous target of $1170.00, a change of 0.85%.
- GF Valueâ„¢ verdict: Current Price $853.40 vs GF Valueâ„¢ $1267.04 = 32.6% undervalued
- GF Scoreâ„¢: 80/100, indicating strong overall performance
- Financial Strength: 10/10, showcasing a robust balance sheet
What's Behind the Analyst Rating?
The adjustment in price target by Morgan Stanley reflects a cautious optimism regarding argenx's future performance. The "Overweight" rating suggests that analysts believe the stock will outperform the market, which is supported by the company's strong fundamentals and growth potential in the biotechnology sector.
Argenx SE is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. With a market capitalization of approximately $57.73 billion, argenx is positioned in the healthcare sector, specifically within the biotechnology industry. The company has made significant strides with its lead product, Vyvgart, which has received multiple FDA approvals for various conditions.
Is ARGX Overvalued or Undervalued?
According to GuruFocus, the GF Valueâ„¢ for argenx is $1267.04, which indicates that the stock is currently undervalued by approximately 32.6%. This margin of safety suggests that investors may find a favorable entry point at the current price of $853.40. The P/E (TTM) ratio stands at 37.93x, which is slightly above the 5-year median P/E of 36.48x, indicating that while the stock is trading at a premium, its growth prospects may justify the valuation. For more details, visit the GF Valueâ„¢ page.
What Does ARGX's GF Scoreâ„¢ Tell Us?
The GF Scoreâ„¢ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Scoreâ„¢ values have been found to generate higher long-term returns (backtested 2006-2021).
| Metric | Rating |
|---|---|
| GF Scoreâ„¢ | 80 |
| Financial Strength | 10/10 |
| Profitability | 4/10 |
| Growth | 9/10 |
| Valuation | 4/10 |
| Momentum | 9/10 |
Argenx's strengths lie in its financial stability and growth potential, as indicated by its high Financial Strength and Growth rankings. However, the Profitability and Valuation ranks suggest there may be room for improvement in these areas. For more information, visit the ARGX stock page.
What Are Insiders Doing with ARGX Stock?
There has been no insider buying or selling activity reported in the last three months, indicating that insiders may be holding their positions and are optimistic about the company's future performance.
What This Means for Investors
With a price target increase and a strong GF Scoreâ„¢, argenx appears to be a compelling option for investors looking for growth in the biotechnology sector. The significant undervaluation indicated by the GF Valueâ„¢ further supports the bullish outlook on the stock.
For the complete analysis, visit the ARGX stock page. You can also use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions
What is ARGX's GF Scoreâ„¢?
ARGX's GF Scoreâ„¢ is 80/100, indicating strong overall performance based on various financial metrics.
Is ARGX overvalued or undervalued?
ARGX is currently undervalued by approximately 32.6%, with a GF Valueâ„¢ of $1267.04 compared to its current price of $853.40.
What do analysts recommend for ARGX?
Analysts maintain an "Overweight" rating on ARGX, suggesting they believe the stock will outperform the market.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
